Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Zai Lab 和 Innoviva Specialtics Therapeutics 宣佈 XACDURO (R)（舒巴克坦或 SUL-DUR）在中國獲得 Zai Lab 和呼吸機相關性肺炎的國家藥品監督管理局批准 >ZLAB
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊